Ponvory
(ponesimod)Ponvory 2 MG Oral TabletPonvory 3 MG Oral Tablet
View 9 more
NO BOXED WARNING
Dosage & administration
drug label
Ponvory prescribing information
Financial Assistance
Financial Assistance Programs
Ponvory retails for $9,609 per dose without insurance or financial assistance.Depending on your patient's insurance situation and other eligibility criteria, they may be able to get Ponvory for significantly less. Review the program information below to determine what program can offer your patient the most benefits.CoPay Card Program$0 Co Pay
Available for
commercial
Program Details
- $9609 for Tablet
- Program Expires Calendar year
- $18000 Annual Cap
Forms
patient education
Ponvory patient education
To share resource; ask patient to:
1.Pull out phone
2.Open camera
3.Scan QR code with camera
4.Tap link
Patient toolkit
Learn More
people also ask
Ponvory FAQs
1. What is the risk summary for PONVORY use during pregnancy?There are no adequate and well-controlled studies of PONVORY in pregnant women. Animal studies have shown adverse effects on development, including fetal malformations and embryolethality. The receptor affected by PONVORY has an important role in embryogenesis.
2. What is the background risk of major birth defects and miscarriage in the general population and for the indicated population?In the US general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2%-4% and 15%-20%, respectively. The background risk for the indicated population is unknown.
3. What are the effects of PONVORY on lactation?There are no data on the presence of PONVORY in human milk or its effects on the breastfed infant. However, when PONVORY was administered to female rats during pregnancy and lactation, ponesimod was detected in the plasma of the offspring, suggesting excretion in milk. Consider the benefits of breastfeeding along with the potential adverse effects on the infant and the mother's clinical need for PONVORY.
4. What is the contraceptive recommendation for women of childbearing potential using PONVORY?Before starting PONVORY treatment, women of childbearing potential should be counseled on the serious risk to the fetus and the need for effective contraception during treatment. Effective contraception should continue for approximately one week after stopping treatment.
5. Is PONVORY safe and effective for pediatric use?Safety and effectiveness of PONVORY in pediatric patients have not been established. The available data pertain to juvenile animal toxicity.
6. Are there specific considerations for geriatric use of PONVORY?Clinical studies of PONVORY did not include patients 65 years of age and over to determine potential differences from younger subjects. Use in elderly patients should be cautious, taking into account factors like hepatic, renal, or cardiac function and concomitant diseases or drug therapy.
7. What is the dosage adjustment for hepatic impairment with PONVORY?No dosage adjustment is necessary in patients with mild hepatic impairment (Child-Pugh class A). PONVORY is not recommended for patients with moderate or severe hepatic impairment (Child-Pugh class B and C), as the risk of adverse reactions may be greater.
FAQ Data Source